The Evolving Treatment Landscape in Atopic Dermatitis

Introduction

Pathomechanisms of AD

IL-4 and IL-13 Further Impair Barrier Function: A Vicious Cycle

New Therapeutic Targets for AD

Evolution of Treatment Landscape in AD

Key Challenges in Managing Patients With AD

Evolution of Treatment Landscape in AD (cont)

Current Therapy Recommendations for Patients With AD

Current Therapy Recommendations for Patients With AD (cont)

Real-World Use of Immunosuppressant Therapies for AD

Use of Systemic Therapies in Patients With AD

Dupilumab AD Clinical Development Phase 3 Program

SOLO-1 and SOLO-2: Primary and Secondary Endpoints

SOLO-1 and SOLO-2: Pruritus

SOLO-1 and SOLO-2: Primary and Secondary Endpoints (cont)

CHRONOS: Efficacy Over 52 Weeks

CHRONOS: Sustained Improvements in IGA 0/1 Through 52 Weeks

CAFÉ: Primary Endpoint

CAFÉ: Secondary Endpoints at Week 16

Effect of Dupilumab on Quality of Life

Dupilumab: Safety

Agents Under Investigation

Conclusions

Abbreviations

Abbreviations (cont)